Human Colon Tumors Express a Dominant-negative Form of SIGIRR That Promotes Inflammation and Colitis-associated Colon Cancer in Mice.
By: Junjie Zhao, Katarzyna Bulek, Muhammet Fatih Gulen, Jarod A Zepp, Georgio Karagkounis, Bradley N Martin, Hao Zhou, Minjia Yu, Xiuli Liu, Emina Huang, Paul L Fox, Matthew F Kalady, Sanford D Markowitz, Xiaoxia Li

Department of Immunology, Lerner Research Institute; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
2015-2-4; doi: 10.1053/j.gastro.2015.08.051
Abstract

Background

Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of the Toll-like and interleukin-1 receptor (IL1R) signaling pathways, controls intestinal inflammation and suppresses colon tumorigenesis in mice. However, the importance of SIGIRR in human colorectal cancer development has not been determined. We investigated the role of SIGIRR in development of human colorectal cancer.

Methods

We performed RNA sequence analyses of pairs of colon tumor and non-tumor tissues, each collected from 68 patients. Immunoblot and immunofluorescence analyses were used to determine levels of SIGIRR protein in primary human colonic epithelial cells, tumor tissues, and colon cancer cell lines. We expressed SIGIRR and mutant forms of the protein in Vaco cell lines. We created and analyzed mice that expressed full-length (control) or a mutant form of Sigirr (encoding SIGIRR(N86/102S), which is not glycosylated) specifically in the intestinal epithelium. Some mice were given azoxymethane and dextran sulfate sodium to induce colitis-associated cancer. Intestinal tissues were collected and analyzed by immunohistochemical and gene expression profile analyses.

Results

RNA sequence analyses revealed increased expression of a SIGIRR mRNA isoform, SIGIRRΔE8, in colorectal cancer tissues compared to paired non-tumor tissues. SIGIRRΔE8 is not modified by complex glycans and is therefore retained in the cytoplasm-it cannot localize to the cell membrane or reduce IL1R signaling. SIGIRRΔE8 interacts with and has a dominant-negative effect on SIGIRR, reducing its glycosylation, localization to the cell surface, and function. Most SIGIRR detected in human colon cancer tissues was cytoplasmic, whereas in non-tumor tissues it was found at the cell membrane. Mice that expressed SIGIRR(N86/102S) developed more inflammation and formed larger tumors after administration of azoxymethane and dextran sulfate sodium than control mice; colon tissues from these mutant mice expressed higher levels of the inflammatory cytokines IL17A and IL6 had activation of the transcription factors STAT3 and NFκB. SIGIRR(N86/102S) expressed in colons of mice did not localize to the epithelial cell surface.

Conclusion

Levels of SIGIRR are lower in human colorectal tumors, compared with non-tumor tissues; tumors contain the dominant-negative isoform SIGIRRΔE8. This mutant protein blocks localization of full-length SIGIRR to the surface of colon epithelial cells and its ability to downregulate IL1R signaling. Expression of SIGIRR(N86/102S) in the colonic epithelium of mice increases expression of inflammatory cytokines and formation and size of colitis-associated tumors.



Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

PMID:26344057






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements